Treatment of Churg-Strauss syndrome: Options for the future

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL. 70, 2012, Pages

  Guillevin, L ^a  

^a Université Paris Descartes ^*  (France)

Author keywords

Churg Strauss syndrome; Treatment

Indexed keywords

CELL PROTEIN; CYTOKINE; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEPOLIZUMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OMALIZUMAB; RITUXIMAB; STEROID;

ALLERGY; ASTHMA; BIOLOGICAL THERAPY; BRONCHOSPASM; CELL FUNCTION; CHURG STRAUSS SYNDROME; CYTOTOXICITY; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SCREENING; DRUG TARGETING; DRUG TREATMENT FAILURE; EDITORIAL; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RELAPSE; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; STEROID THERAPY; SURVIVAL RATE; TH2 CELL; TREATMENT RESPONSE;

CHURG-STRAUSS SYNDROME; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; STEROIDS; TREATMENT OUTCOME;

EID: 84863751809     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (3)

1. GUILLEVIN L, PAGNOUX C, SEROR R, MAHR A, MOUTHON L, LE TOUMELIN P; FRENCH VASCULITIS STUDY GROUP (FVSG): The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011; 90: 19-27.
2. GUILLEVIN L: Clinical trials on systemic necrotizing vasculitides. Presse Med 2010; 39: 653-9.
3. MOOSIG F, GROSS WL, HERRMANN K, BREMER JP, HELLMICH B: Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155: 341-3.